Breakthrough in drugs for Huntington’s- subjected to advanced clinical trials

Huntington’s disease is a neurodegenerative disease which is incurable and invariably fatal. It mainly occurs due to a mutation which results in the production of an abnormal form of a protein called huntingtin. In order to overcome the disease, Ionis Pharmaceuticals developed a drug, RG6042 which inhibits the production of the mutant huntingtin. According to early clinical testing, the drug has shown inhibitory effect on huntingtin protein production, thus indicating the necessity in advance testing at this point.